General
Preferred name
MOLSIDOMINE
Synonyms
Morsydomine ()
SIN-10 ()
Corvaton ()
SIN-10, Corvaton, Morsydomine ()
CAS-276 ()
CAS276 ()
NSC-757398 ()
Corvaton Mite ()
Corvasal ()
Cas 276 ()
Molsidomina ()
Corvaton Ret ()
P&D ID
PD001642
CAS
25717-80-0
Tags
available
prodrug
drug
Drug indication
Angina pectoris
Cardiovascular disease
Drug Status
approved
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Molsidomine, a cardiovascular drug, acts in a similar fashion to organic nitrates. The SIN-1A metabolite of molsidomine has a pharmacologically active group of nitric oxide, which increases levels of cyclic GMP, and decreases intracellular calcium ions in smooth muscle cells. This leads to relaxation of smooth muscle in the blood vessels, and inhibits platelet aggregation.; ;
METABOLISM Molsidomine hepatically metabolized to _linsidomine_. Linsidomine releases nitric oxide (NO) from endothelial cells when it decays, and acts as the active vasodilating metabolite responsible for molsidomine's pharmacological effects.; ; Oral absorption of Molsidomine is found to be 95.5% ±4.5. Presystemic metabolism is noted to be 56% and metabolism is reported extensive by Liver. Renal Excretion accounts for 95 % and plasma half-life is 5 hr.; Back to top
DESCRIPTION Molsidomine, a nitric oxide (NO) donor, is an orally active vasodilator agent. Molsidomine is a prodrug that can be rapidly metabolized in the liver to its active metabolite, Linsidomine (HY-101200). Molsidomine can be used for the study of angina pectoris, mental disorders and diabetic complications[1][2].
PRICE 29
DESCRIPTION Vasodilator; converted by the liver to the active metabolite, SIN-1 (LOPAC library)
DESCRIPTION Molsidomine (Corvaton) is an orally active, long-acting vasodilating drug. It metabolizes in the liver to the active metabolite linsidomine, that releases nitric oxide (NO) upon decay as the actual vasodilating compound. (TargetMol Bioactive Compound Library)
Compound Sets
13
Cayman Chemical Bioactives
82200
ChEMBL Drugs
CHEMBL1329455
DrugBank
DB09282
DrugBank Approved Drugs
DB09282
DrugCentral
1831
DrugCentral Approved Drugs
1831
DrugMAP
DM9MA8O
DrugMAP Approved Drugs
DM9MA8O
DrugMatrix
LOPAC library
MedChem Express Bioactive Compound Library
HY-B1069
Selleckchem Bioactive Compound Library
molsidomine
TargetMol Bioactive Compound Library
T0109
External IDs
30
Properties
(calculated by RDKit )
Molecular Weight
242.1
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
1
cLogP
0.09
TPSA
82.78
Fraction CSP3
0.67
Chiral centers
0.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
NOD
Drug Metabolite
Pathway
Immunology/Inflammation
NF-κB
Metabolic Enzyme/Protease
Source data